2023
DOI: 10.1111/jop.13405
|View full text |Cite
|
Sign up to set email alerts
|

lncRNA HOXA11‐AS maintains the stemness of oral squamous cell carcinoma stem cells and reduces the radiosensitivity by targeting miR‐518a‐3p/PDK1

Abstract: Objective: Oral squamous cell carcinoma (OSCC) is the most prevailing oral malignancy. The lncRNA HOXA11-AS shows prominent roles in OSCC. This study explored the effects of lncRNA HOXA11-AS on regulating OSCC stem cell stemness and radiosensitivity by targeting miR-518a-3p/PDK1. Methods: Human OSCC cell lines SCC9 and SCC15 were selected. CD133 + cancer stem cells (CSCs) were sorted by immunomagnetic beads. CD133 expression in cells and HOXA11-AS expression in SCC9, SCC15, and CD133 + SCC9, CD133 + SCC15 cell… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
4

Relationship

0
4

Authors

Journals

citations
Cited by 4 publications
(1 citation statement)
references
References 26 publications
0
1
0
Order By: Relevance
“…MAGI2-AS3 can regulate the expression of target genes GDPD5 and SEC61A1 through sponge miR-2185p, thereby regulating the proliferation, migration and EMT of NPC cells, as well as the cisplatin resistance of NPC ( 22 ). HOXA11-AS is pivotal in various cancers such as lung adenocarcinoma ( 44 ), oral squamous cell carcinoma ( 45 ), gastric cancer ( 46 ), prostate cancer ( 47 ), and breast cancer ( 48 ) and is closely related to NPC. HOXA11-AS is increasingly expressed in cisplatin-resistant NPC cells and knocking down HOXA11-AS could increase the expression of miR-454-3p and inhibit the expression of target gene c-Met, thereby increasing the sensitivity of the tumor cells to cisplatin ( 23 ).…”
Section: Role Of Incrna In Npc Chemotherapy Resistancementioning
confidence: 99%
“…MAGI2-AS3 can regulate the expression of target genes GDPD5 and SEC61A1 through sponge miR-2185p, thereby regulating the proliferation, migration and EMT of NPC cells, as well as the cisplatin resistance of NPC ( 22 ). HOXA11-AS is pivotal in various cancers such as lung adenocarcinoma ( 44 ), oral squamous cell carcinoma ( 45 ), gastric cancer ( 46 ), prostate cancer ( 47 ), and breast cancer ( 48 ) and is closely related to NPC. HOXA11-AS is increasingly expressed in cisplatin-resistant NPC cells and knocking down HOXA11-AS could increase the expression of miR-454-3p and inhibit the expression of target gene c-Met, thereby increasing the sensitivity of the tumor cells to cisplatin ( 23 ).…”
Section: Role Of Incrna In Npc Chemotherapy Resistancementioning
confidence: 99%